GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Minapharm Pharmaceuticals (CAI:MIPH) » Definitions » EV-to-EBITDA

Minapharm Pharmaceuticals (CAI:MIPH) EV-to-EBITDA : 6.43 (As of Jun. 25, 2025)


View and export this data going back to 2004. Start your Free Trial

What is Minapharm Pharmaceuticals EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Minapharm Pharmaceuticals's enterprise value is E£5,727 Mil. Minapharm Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was E£891 Mil. Therefore, Minapharm Pharmaceuticals's EV-to-EBITDA for today is 6.43.

The historical rank and industry rank for Minapharm Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:

CAI:MIPH' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.67   Med: 13.98   Max: 19.11
Current: 6.42

During the past 3 years, the highest EV-to-EBITDA of Minapharm Pharmaceuticals was 19.11. The lowest was 5.67. And the median was 13.98.

CAI:MIPH's EV-to-EBITDA is ranked better than
81.86% of 733 companies
in the Drug Manufacturers industry
Industry Median: 13.82 vs CAI:MIPH: 6.42

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-06-25), Minapharm Pharmaceuticals's stock price is E£248.75. Minapharm Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was E£10.453. Therefore, Minapharm Pharmaceuticals's PE Ratio (TTM) for today is 23.80.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Minapharm Pharmaceuticals EV-to-EBITDA Historical Data

The historical data trend for Minapharm Pharmaceuticals's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Minapharm Pharmaceuticals EV-to-EBITDA Chart

Minapharm Pharmaceuticals Annual Data
Trend Dec22 Dec23 Dec24
EV-to-EBITDA
2.44 9.65 4.03

Minapharm Pharmaceuticals Quarterly Data
Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24
EV-to-EBITDA Get a 7-Day Free Trial - 9.65 37.51 19.95 4.03

Competitive Comparison of Minapharm Pharmaceuticals's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Minapharm Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Minapharm Pharmaceuticals's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Minapharm Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Minapharm Pharmaceuticals's EV-to-EBITDA falls into.


;
;

Minapharm Pharmaceuticals EV-to-EBITDA Calculation

Minapharm Pharmaceuticals's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=5727.051/891.081
=6.43

Minapharm Pharmaceuticals's current Enterprise Value is E£5,727 Mil.
Minapharm Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was E£891 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Minapharm Pharmaceuticals  (CAI:MIPH) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Minapharm Pharmaceuticals's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=248.75/10.453
=23.80

Minapharm Pharmaceuticals's share price for today is E£248.75.
Minapharm Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was E£10.453.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Minapharm Pharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Minapharm Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Minapharm Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
El-Bardissi Street, 2T Takseem Asmaa Fahmy Street, Heliopolis, Cairo, EGY
Minapharm Pharmaceuticals is a company whose purpose is to produce medicines and chemicals. medical supplies. cosmetics, veterinary medicines, dental supplies, and the production of dietary supplements and herbal medicines. It produces drugs for many segments such as biogenetics, orthopedic, ophthalmology, miscellaneous, dermatology, gastroenterology, cardiology, and uro-gynaecology lines.

Minapharm Pharmaceuticals Headlines

No Headlines